KRAS and familial pancreatic carcinoma: Engineered bEVs also act as RNA delivery vehicles; encapsulation of siRNAs targeting oncogenic KRAS mutations has suppressed tumor growth in pancreatic cancer models, suggesting translational potential for KRAS-driven LC [14,119].